Targeting– tag –
-
RiboX Therapeutics Receives FDA IND Clearance for RXIM002, the First Circular RNA-Based In Vivo CAR Therapy for Autoimmune Cytopenias
BioSpace USA Overview RiboX Therapeutics has received FDA Investigational New Drug (IND) clearance for RXIM002, a circular RNA (circRNA)-based in vivo CAR therapy targeting autoimmune cytopenias. RXIM002 is the first in vivo CAR therapy ... -
BioInformant Analyzes the Rise of Exosome Therapeutics in 2026: Potential as a Novel Modality Leveraging Intercellular Communication for New Treatments
BioInformant (Blog) USA Overview BioInformant's blog analyzes the growing role of exosome therapeutics in 2026, highlighting these extracellular vesicles as an emerging treatment modality. Exosomes, lipid bilayer vesicles 30-150 nanomete... -
Fate Therapeutics Initiates Phase 2 Trial for iPSC-Derived Off-the-Shelf CAR T-Cell Therapy FT819 in Lupus Nephritis, Gains FDA IND Approval for Autoimmune FT839
Fate Therapeutics, Inc. (Press Release) USA Overview Fate Therapeutics reported significant advancements in its iPSC-derived off-the-shelf CAR T-cell immunotherapy pipeline, with the first patient dosed in the Phase 2 RECLAIM-LN study of... -
Intellia Therapeutics Advances CRISPR Gene Editing: Lonvo-z Achieves Phase 3 Success for HAE, Targeting Mid-2027 U.S. Launch; Nex-z Phase 3 Enrollment Resumes for ATTR
Intellia Therapeutics, Inc. (Press Release) USA Overview Intellia Therapeutics reported positive Phase 3 results for lonvo-z in hereditary angioedema (HAE), with a Biologics License Application (BLA) submission to the FDA planned for H2 ... -
Liv Hospital Accelerates iPSC Therapy with Bioreactor Investment, Targeting Parkinson’s Disease
Liv Hospital Turkey Overview Liv Hospital is addressing the critical challenge of safe and efficient mass production of induced pluripotent stem cells (iPSCs) through a major investment in advanced bioreactor systems. This initiative aim... -
Intellia Therapeutics Reports Positive Phase 3 HAELO Data for lonvo-z in HAE and Resumes Nex-z ATTR Phase 3 Enrollment
Intellia Therapeutics USA Overview Intellia Therapeutics announced positive Phase 3 HAELO clinical data for lonvo-z in hereditary angioedema (HAE), published in the New England Journal of Medicine. The company anticipates FDA Biologics L... -
CRISPR Gene Editing Therapies Limited to Ex Vivo Approvals for Sickle Cell and Beta-Thalassemia in 2026; In Vivo Candidates Show 87% Attack Reduction and 62% Cholesterol Decrease
DeepDNA USA Overview As of August 2026, the only globally approved CRISPR gene-editing therapies are ex vivo treatments for sickle cell disease and transfusion-dependent beta-thalassemia. However, in vivo therapies are demonstrating sign... -
Washington University Reports Promising Early Results for Aggressive Blood Cancers with Combined CRISPR Gene Editing and Stem Cell Transplant
The Brighter Side of News USA Overview Researchers at Washington University School of Medicine in St. Louis reported promising early results from a clinical trial combining CRISPR gene editing with stem cell transplantation to treat aggr... -
Umoja Biopharma Initiates Phase 1/2 Trials for In Vivo CAR-T Therapies UB-VV400 and UB-VV500 Targeting B-Cell Malignancies and Multiple Myeloma
Gene Therapy Net (ClinicalTrials.gov) USA Overview Umoja Biopharma is set to initiate Phase 1/2 clinical trials for its investigational in vivo CAR-T cell therapies, UB-VV400 for recurrent/refractory B-cell malignancies and UB-VV500 for ... -
3D Bioprinting Innovator Partners with MedTech Giant to Commercialize Regenerative Therapies
Specialized Media / Company Announcement USA Overview A pioneering 3D bioprinting company has announced a strategic licensing agreement with a leading medical device manufacturer, targeting the regenerative medicine sector. This partners...
